UBS Group
TYRA icon

UBS Group’s Tyra Biosciences TYRA Stock Holding History

UBS Group’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Buy
129,945
+68,384
+111% +$2.26M ﹤0.01% 4369
2026
Q1 		$2.36M Buy
61,561
+2,705
+5% +$87.6K ﹤0.01% 4823
2025
Q4 		$1.55M Sell
58,856
-288
-0.5% -$5.29K ﹤0.01% 5193
2025
Q3 		$827K Buy
59,144
+12,876
+28% +$147K ﹤0.01% 5720
2025
Q2 		$443K Sell
46,268
-18
-0% -$171 ﹤0.01% 6109
2025
Q1 		$430K Sell
46,286
-1,565
-3% -$20.3K ﹤0.01% 5965
2024
Q4 		$665K Buy
47,851
+36,887
+336% +$669K ﹤0.01% 5644
2024
Q3 		$258K Buy
10,964
+3,389
+45% +$71.1K ﹤0.01% 5691
2024
Q2 		$121K Sell
7,575
-6,597
-47% -$114K ﹤0.01% 6040
2024
Q1 		$232K Buy
14,172
+9,195
+185% +$151K ﹤0.01% 5748
2023
Q4 		$68.9K Sell
4,977
-333
-6% -$4.31K ﹤0.01% 6377
2023
Q3 		$73.1K Sell
5,310
-2,687
-34% -$39.8K ﹤0.01% 6049
2023
Q2 		$136K Buy
7,997
+3,378
+73% +$49K ﹤0.01% 5767
2023
Q1 		$74.2K Buy
4,619
+1,032
+29% +$12.3K ﹤0.01% 6145
2022
Q4 		$27.3K Buy
3,587
+3,496
+3,842% +$24.7K ﹤0.01% 7344
2022
Q3 		$1K Buy
+91
New +$832 ﹤0.01% 10046
2022
Q2 		– Sell
-1,740
Closed -$19K – 10959
2022
Q1 		$19K Sell
1,740
-3,733
-68% -$44.3K ﹤0.01% 7522
2021
Q4 		$77K Buy
+5,473
New +$109K ﹤0.01% 6533

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

UBS Group's TYRA Position: Q2 2026 in Review

UBS Group increased its Tyra Biosciences (TYRA) stake by 111% in Q2 2026, buying an estimated $2.26M and bringing the position to 129,945 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4369.

UBS Group first reported a position in TYRA in Q4 2021 and has held it in 18 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • UBS Group held 129,945 shares of Tyra Biosciences worth $4.15M as of Q2 2026.
  • UBS Group bought 68,384 Tyra Biosciences shares in Q2 2026, an estimated $2.26M.
  • Tyra Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4369 holding.
  • UBS Group first reported a position in Tyra Biosciences in Q4 2021 and has held it in 18 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.